SCHEMBL23744157

SCHEMBL23744157

Cc1cnc(N2C[C@@H](C)N[C@@H](C)C2)nc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 4/20 0.44
BCL6 P41182 2/20 0.38
NCOR2 Q9Y618 1/20 0.38
ACACB O00763 1/20 0.36
GPR119 Q8TDV5 2/20 0.36
AOC3 Q16853 1/20 0.36
KCNH2 Q12809 2/20 0.34
TGFBR1 P36897 1/20 0.34
ACVR1 Q04771 1/20 0.34
SCN9A Q15858 1/20 0.34
HDAC1 Q13547 1/20 0.33
AURKA O14965 1/20 0.33
DHFR P00374 1/20 0.33
OGA O60502 1/20 0.33
FGFR1 P11362 1/20 0.32
HTT P42858 1/20 0.32
EIF2AK4 Q9P2K8 1/20 0.32
TSHR P16473 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23744047 0.83 PTPN11 (0.51) PTPN11BCL6NCOR2ACACBGPR119
SCHEMBL23744770 0.83 PTPN11 (0.43) PTPN11BCL6NCOR2SCN9A
SCHEMBL15725788 0.83 PTPN11 (0.49) PTPN11BCL6NCOR2SCN9AHDAC1
SCHEMBL23744086 0.83 PTPN11 (0.43) PTPN11BCL6NCOR2KCNH2TGFBR1
SCHEMBL23744751 0.83 PTPN11 (0.51) PTPN11BCL6NCOR2ACACBGPR119
SCHEMBL24945764 0.83 PTPN11 (0.43) PTPN11BCL6NCOR2SCN9AHDAC1
SCHEMBL17972943 0.82 TSHR (0.39) ACACBGPR119AOC3KCNH2DHFR
SCHEMBL16472351 0.82 ACACB (0.39) ACACBGPR119AOC3KCNH2DHFR
SCHEMBL23744161 0.81 ACACB (0.43) PTPN11BCL6NCOR2ACACBSCN9A
SCHEMBL23560718 0.80 ROCK2 (0.41) GPR119ACVR1HDAC1FGFR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 PTPN11 1801/4885BCL6 4736/4885NCOR2 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.